SCHEDULE: BlackRock Portfolio Management Discloses 4.7% Passive Stake in Stoke Therapeutics

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.7% of Stoke Therapeutics, Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock Portfolio Management LLC reported beneficial ownership of 2,550,341 shares of Stoke Therapeutics, Inc. common stock.
• This represents 4.7% of the total class of securities.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment.
• The reporting person has sole voting power over 2,412,388 shares and sole dispositive power over 2,550,341 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a passive investment by a major institutional investor, BlackRock, in Stoke Therapeutics. While it doesn't indicate any negative news, it also doesn't provide specific positive operational or financial updates for the company. The holding is significant but below the 5% threshold for more active reporting.

Positives

• BlackRock Portfolio Management LLC, a significant institutional investor, holds a substantial stake in Stoke Therapeutics, Inc., indicating institutional interest.
• The investment is passive, suggesting a long-term holding strategy rather than an activist intent.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s future performance or BlackRock's investment strategy beyond the passive nature of the holding.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This Schedule 13G filing reflects a routine disclosure of institutional ownership by a major asset manager, BlackRock, in a biotechnology company, Stoke Therapeutics. Such filings are common and indicate ongoing portfolio management activities within the broader investment landscape, without specific implications for the biotechnology industry trends themselves.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can be viewed as a vote of confidence.
• Management: Awareness of a large, passive institutional investor on their shareholder register.

Next Steps

• BlackRock Portfolio Management LLC will continue to monitor its investment in Stoke Therapeutics, Inc.
• Further Schedule 13G amendments would be filed if there are significant changes in beneficial ownership (e.g., crossing 10% or dropping below 5% if previously above).

Key Dates

Keywords

Stoke Therapeutics, BlackRock Portfolio Management, Schedule 13G, Common Stock, Passive Investment, Institutional Ownership, SEC Filing, STOK